Advanced search
Publication Cover
Hematology Volume 23, 2018 - Issue 4
Submit an article Journal homepage
3,575
Views
8
CrossRef citations to date
0
Altmetric
Myeloproliferative Disease

Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Seniz OngorenDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Ahmet Emre EskazanDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-9568-0894
ORCID Icon,
Veysel SuzanDepartment of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Sercan SavciDepartment of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Isil Erdogan OzunalDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Selin BerkDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Fevzi Fırat YalnizDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Tugrul ElverdiDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Ayse SalihogluDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Yucel ErbilginDepartment of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
,
Sibel Aylin IseriDepartment of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
,
Muhlis Cem ArDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Zafer BaslarDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Yildiz AydinDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Nukhet TuzunerDepartment of Pathology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
,
Ugur OzbekDepartment of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey
&
Teoman SoysalDivision of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
 show all
Pages 212-220 | Published online: 09 Oct 2017

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ahmet Emre Eşkazan, Rıdvan Ali, Ebru Alnıgeniş, Orhan Ayyıldız, İbrahim Haznedaroğlu, Onur Kırkızlar, Erdal Kurtoğlu, Simten Malhan, Ergün Öksüz, Özlem Polat, Güray Saydam, Mehmet Sönmez, Selami Koçak Toprak, Tayfur Toptaş & Mehmet Turgut. (2022) Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology 15:2, pages 97-106.
Read now
Yucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, Ayse Salihoglu, Tugrul Elverdi, Sinem Firtina, Orcun Tasar, Sevcan Mercan, Sinem Sisko, Khusan Khodzhaev, Seniz Ongoren, Muhlis Cem Ar, Zafer Baslar, Teoman Soysal, Muge Sayitoglu & Ugur Ozbek. (2019) Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia & Lymphoma 60:1, pages 200-207.
Read now

Articles from other publishers (6)

Ahmet Emre Eşkazan. (2021) Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood Cancer Journal 11:4.
Crossref
Leimarembi Devi Naorem, Mathavan Muthaiyan, Ishita Bhattacharyya, Dinakara Rao Ampasala & Amouda Venkatesan. 2021. A Theranostic and Precision Medicine Approach for Female-Specific Cancers. A Theranostic and Precision Medicine Approach for Female-Specific Cancers 31 47 .
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Manila Gaddh, Brittany Hill, Jessica Neely, Angela Hatcher, Meena Joseph, Martha Arellano, Fuad El-Rassi, Audrey Kim, Jean Hanna Khoury & Vamsi K. Kota. (2020) Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Journal of Clinical Medicine 9:5, pages 1542.
Crossref
Mario Tiribelli & Ahmet Emre Eskazan. (2019) Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. Oncology and Therapy 7:2, pages 95-100.
Crossref
Robert RoskoskiJr.Jr.. (2019) Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research 144, pages 19-50.
Crossref
Mario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, Alessandra Iurlo, Francesca Cibien, Elena Maino, Anna Guella, Gianluca Festini, Claudia Minotto, Ercole De Biasi, Federico De Marchi, Luigi Scaffidi, Luca Frison, Cristina Bucelli, Marta Medeot, Elisabetta Calistri, Rosaria Sancetta, Manuela Stulle, Nicola Orofino, Mauro Krampera, Filippo Gherlinzoni, Gianpietro Semenzato, Giovanni Pizzolo, Achille Ambrosetti & Renato Fanin. (2018) Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget 9:18, pages 14219-14227.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.